3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Multiple Myeloma
3
Breast Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
1
Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer
1
Recurrence
1
Patient Preference
1
Neoplasms
1
Lymphoma, Non-Hodgkin
1
Inflammatory Breast Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
CD20-positive Hematological Malignancies
1
Bile Duct Neoplasms
1
Advanced Cancers
1
Interventions
Paclitaxel
7
Cyclophosphamide
6
Doxorubicin
5
pembrolizumab
3
Trastuzumab
3
Taxes
3
Specimen Handling
3
Carboplatin
3
pertuzumab
2
eribulin
2
Radiotherapy
2
Epirubicin
2
Docetaxel
2
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
ruxolitinib
1
pegfilgrastim
1
onvansertib
1
olaparib
1
neratinib
1
durvalumab
1
cobimetinib
1
atezolizumab
1
X-Rays
1
Therapeutics
1
Tamoxifen
1
Surgical Procedures, Operative
1
Radiation
1
Peripheral Blood Stem Cell Transplantation
1
Panitumumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Inflammatory Breast Neoplasms
×
Injections, Subcutaneous
×
1 year
×
Clear all
NCT05415215
2026-02-10
ProHer
Hoffmann-La Roche
Phase 3
Completed
346 enrolled
20 charts